A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
Cabozantinib and Pembrolizumab in Metastatic Pancreas
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
- Status
- RECRUITING
- Phase
- NA
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- Status
- COMPLETED
- Phase
- PHASE2
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Status
- COMPLETED
- Phase
- PHASE2